The lowest-priced brand-new, unused, unopened, undamaged item in its original packaging (where packaging is applicable).Packaging should be the same as what is found in a retail store, unless the item is handmade or was packaged by the manufacturer in non-retail packaging, such as an unprinted box or plastic bag.See details for additional description.
The Complement FactsBook contains entries on all components of the Complement System, including C1q and Lectins, C3 Family, Serine Proteases, Serum Regulators of Complement Activation, Cell Surface Proteins, and Terminal Pathway Proteins. Domain Structure diagrams are incorporated to clearly illustrate the relationships between all the complement proteins, both within families and between families. The FactsBook also includes the cDNA sequences, marked with intron/exon boundaries, which will facilitate genetic studies.
Dr. Bernard Morely is a senior lecturer in the Division of Medicine of the Imperial College School of Medicine. He studied biochemistry at Liverpool University before training for his doctorate at Oxford in the late Dr. Rodney Porter's unit. Here he worked on cloning Factor B with Duncan Campbell. After several years of work in the USA and the UK on globin expression and its regulation, he returned to complement research at the Hammersmith Hospital. His present research interests are in the genetics of SLE and the regulation of gene expression. Professor Mark Walport is a professor of medicine and the head of the Division of Medicine at Imperial College School of Medicine. He was previously Director of Research and Development fot the Hammersmith Hospitals Trusts. He trained at Cambridge University and the Middlesex Hospital Medical School. After junior clinical training posts, he undertook a Ph.D. in Cambridge supervised by Professor Peter Lachmann. From there he moved in 1985 to the Royal Postgraduate Medical School at Hammersmith Hospital. His research interests are in the genetics of the complement system and in the inherited mechanisms of susceptibility to autoimmune rheumatic diseases.